Also trades as: 4967.T (JPX) · $vol 12M
KBYPF OTC
Kobayashi Pharmaceutical Co., Ltd.
1W: +15.9%
1M: +15.9%
3M: +15.9%
YTD: +14.0%
1Y: +5.5%
3Y: -26.9%
5Y: -51.5%
$39.47
+0.00 (+0.00%)
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Income Trends
Revenue
$165.9B
+0.2% ▲
5Y CAGR: +2.0%
Gross Profit
$79.5B
-9.2% ▼
5Y CAGR: -1.4%
Operating Income
$14.9B
-40.2% ▼
5Y CAGR: -10.5%
Net Income
$3.7B
-63.7% ▼
5Y CAGR: -28.2%
EPS (Diluted)
$48.62
-64.1% ▼
5Y CAGR: -27.7%
EBITDA
$23.6B
+7.5% ▲
5Y CAGR: -4.6%
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $155.3B | $166.3B | $173.5B | $165.6B | $165.9B |
| YoY Growth | +3.1% | +7.1% | +4.3% | -4.5% | +0.2% |
| Cost of Revenue | $66.5B | $73.9B | $77.1B | $78.0B | $86.4B |
| Gross Profit | $88.8B | $92.3B | $96.4B | $87.6B | $79.5B |
| Gross Margin | 57.2% | 55.5% | 55.6% | 52.9% | 47.9% |
| R&D Expenses | $7.5B | $8.3B | $9.0B | $9.1B | $9.1B |
| SG&A Expenses | $31.8B | $31.6B | $57.6B | $22.0B | $54.3B |
| Operating Expenses | $62.7B | $65.7B | $70.6B | $62.7B | $64.6B |
| Operating Income | $26.1B | $26.7B | $25.8B | $24.9B | $14.9B |
| Operating Margin | 16.8% | 16.0% | 14.9% | 15.0% | 9.0% |
| Interest Expense | $18M | $18M | $29M | $28M | $28M |
| Income Before Tax | $27.6B | $27.9B | $27.6B | $13.9B | $3.7B |
| Tax Expense | $7.9B | $7.9B | $7.2B | $3.8B | $83M |
| Net Income | $19.7B | $20.0B | $20.3B | $10.1B | $3.7B |
| Net Margin | 12.7% | 12.0% | 11.7% | 6.1% | 2.2% |
| EPS (Diluted) | $252.36 | $259.59 | $268.16 | $135.42 | $48.62 |
| EBITDA | $30.8B | $31.9B | $33.6B | $22.0B | $23.6B |
| Shares Outstanding | 78M | 77M | 76M | 74M | 74M |